Medicare Will Cover FDA-Approved Alzheimer’s Treatments with Registry to Track Outcomes

• June 02, 2023

Medicare Part B enrollees will have access to new treatments for Alzheimer’s disease if the Food and Drug Administration (FDA) grants traditional approval and their clinicians participate in a registry to track real-world evidence of the therapy's effects, the Centers for Medicare & Medicaid Services (CMS) said June 1.

ARTICLE TAGS

• Government Reimbursement